IA Medical raised €1.4 million to distribute its chatbot designed to support Alzheimer’s patients
The startup, which was established in Lyon in 2020, has developed Alix, a chatbot to support and make life easier for caregivers and Alzheimer’s sufferers. Its mission is to help them access resources appropriate for their needs (practical information on assistance, contact details for specialized services, advice on managing their day-to-day life, exercises, etc.). The €1.4 million funding operation, announced on June 2, will allow IA Medical to move towards commercialization, although a free version is expected to be available in September (it will become a paying service over the course of 2024). The startup also intends to expand its teams and strengthen its market presence. The Klesia investment fund and Bpifrance contributed €650,000, with the remainder being provided by private investors via a capital offering.
Santexpat raised €3 million
On June 13, the specialist healthcare coverage insurance platform for French expats announced a €3 million Series A financing round. Leading insurance companies Malakoff Humanis (via its MH Innov’ fund), and Swiss Life France, took the opportunity to take a stake in the company as strategic industrial investors. The Accurafy4 investment fund, shareholder since 2020, BNP Paribas and Bpifrance also took part in this financing round. The funds raised will be used to accelerate the roll-out of the strategy developed, for now via organic growth. Launched in 2019, Santexpat is the first fully digital health insurance and services platform to target the 3 million French expats living abroad.
Anoat Therapeutics raised €2 million to fight cystic fibrosis
On June 19, Anoat announced that it had raised €2 million in seed funding from AdBio Partners, a venture capital company specialized in seed investments in biotechnology. The biotech company will use the funds to carry out in vivo and in vitro pharmacological evaluations and select a clinical drug candidate, that will offer a transformative, mutation-agnostic treatment option for cystic fibrosis patients. Created in 2023, Anoat is the first startup resulting from the alliance between AdBio Partners and Inserm Transfert.
BrainTale raised €4.5 million to improve the diagnosis of neurodegenerative diseases
Founded in 2018, BrainTale, which specializes in the brain’s white matter announced on June 20 that it had raised €4.5 million from Capital Grand Est and the MACSF, as well as from business angels, to accelerate its development in Europe and the United States. BrainTale has developed a platform of digital biomarkers to support diagnosis and clinical decision-making, particularly in the monitoring of neurodegenerative diseases or traumatic brain injuries, thanks to sensitive and reliable measurements of alterations in white matter microstructure.
CorWave raised €61 million for its blood pump
The second closing of the Series C funding announced by CorWave on June 20 is led by the Société de projets industriels (SPI) fund, managed on behalf of the French government by Bpifrance as part of France 2030 (€15 million), and European investors and entrepreneurs with strong industrial roots (€11 million), including Exor Ventures, controlled by the Agnelli family (Ferrari, Stellantis), and Vlerick Group (textiles and metallurgy). As a result of this operation CorWave will be able to finance the next stages of its development. The high-tech company has already embarked upon its industrial transformation, and will shortly be opening its new factory in Clichy, at the heart of the Greater Paris area, on the banks of the Seine. Founded in 2012, CorWave designs next-generation blood pumps (circulatory assistance devices) that use breakthrough technology – the undulating membrane pump.
Ilasis Laser raised €4.4 million to democratize laser cataract surgery
The €4.4 million funding operation was announced on June 20, and completed via a pool of Business Angels, IRDI Capital Investissement and Nouvelle Aquitaine COinvestissement (NACO). These funds will finance the commercial development of Ilasis Laser’s Rx product in Europe and the FDA approval required for marketing in the United States.
Founded in 2019, Ilasis Laser designs, manufactures and markets Rx, the first femtosecond laser surgical instrument dedicated to cataract surgery. Cataracts are the leading cause of blindness around the world. Rx simplifies the procedure and allows a perfectly predictable and reproducible laser cutting to be performed.
Numa Health secured financing of €4 million
On June 23, the startup Numa Health announced a €4 million funding operation to speed up developments in personalized, preventive and predictive medicine. The Inovie medical biology group, the RSOLUTIONS fund managed by independent French asset management company RGREEN INVEST, the public investment bank Bpifrance and the Groupe Pasteur Mutualité mutual insurance and services group all acquired a stake in the company. The startup, which is based in La Rochelle on the France’s Atlantic coast, was established in 2019 by a former osteopath, karate practitioner and researcher in medical bioinformatics. The algorithms the company has developed detect metabolic imbalances from a simple blood test, and determine a health score which includes explanations and personalized recommendations (nutrition, sports or cognitive practice, lifestyle…).
Astraveus raised €16.5 million for its automated microfluidic Cell and Gene therapy manufacturing platforms
On June 27, Astraveus announced a €16.5 million Series Seed financing led by AdBio Partners, syndicated with M Ventures, Johnson & Johnson Innovation – JJDC Inc. and Bpifrance ,via its Large Venture fund, to accelerate the development of its Cell and Gene Therapy (CGT) biomanufacturing platform and attract additional talent. Lakhesys is an all-in-one platform based on innovative microfluidic technologies designed to optimize and miniaturize bioproduction processes. It removes the need for large-scale infrastructure, reducing costs and processing time, and overcoming the logistical challenges associated with CGT manufacturing. Established in 2016, Astraveus aims to democratize access to these cutting-edge therapies.
Gleamer raised €27 million in Series B financing for its artificial intelligence platform designed to assist radiologists
The €27 million equity financing round, announced on June 28, was led by Supernova Invest, followed by Heal Capital, with the participation of its historical partners XAnge, Elaia, Bpifrance via the Digital Venture fund and Fonds Ambition Amorçage Angels (F3A) of France 2030 (ex Investment for the Future Program – PIA), MACSF, Crista Galli Ventures, UI Investissement, as well as several European radiologists. This operation will enable Gleamer to expand its portfolio of solutions and strengthen its European and U.S. teams, while accelerating its international business development. Total funds raised to date amount to €36 million (€7.5 million in Series A in 2020 and a seed round of €1.5 million in 2018).
Founded in 2017, Gleamer offers a complete catalog of solutions in the area of standard radiology with BoneView for the detection of traumatic bone lesions, ChestView for the detection of pulmonary pathologies, BoneMeasurement for the automation of osteoarticular measurements and BoneAge for the automation of bone age estimation.
Carthera raised €37.5 million in a Series B financing round
Founded in 2010, Carthera manufactures SonoCloud®, an innovative ultrasound-based medical device designed to treat a wide range of brain disorders. The €37.5 million financing round announced on June 30 was led by a leading investor (undisclosed), alongside the European Innovation Council Fund (EICF) and historical investors including Panakès Partners, Relyens Innovation Santé (Turenne Santé) and Supernova Invest via its Supernova 2 fund. These new funds will enable the medtech company to launch a pivotal multicenter clinical trial in patients with recurrent glioblastoma, and further advance its clinical pipeline.
Exeliom Biosciences raised €8 million for its anti-cancer treatment
Exeliom‘s flagship drug candidate, EXL01, has received an additional €8 million to support its development, thanks to a financing operation led by a new entrant to the company’s capital, CE Ventures, which is joining historical investors Auriga Partners, UI Investissement and the Biocodex laboratory. This completes a total Series A financing of €24 million, started in 2018. This treatment is currently in the clinical phase for Crohn’s disease. This latest tranche of funding, announced on June 30, will be used to launch four new trials, for gastric cancer, non-small cell lung cancer, hepatocellular carcinoma, and the prevention of the recurrence of Clostridium difficile infection. Founded in 2016, Exeliom is working to develop immunotherapies derived from the microbiome.